Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Up 44.1% in June

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) saw a large growth in short interest in June. As of June 15th, there was short interest totalling 78,700 shares, a growth of 44.1% from the May 31st total of 54,600 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 51,500 shares, the short-interest ratio is presently 1.5 days.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on Eton Pharmaceuticals in a report on Monday, May 6th. They issued a “buy” rating and a $8.00 target price on the stock.

Eton Pharmaceuticals Trading Up 3.3 %

Shares of NASDAQ ETON traded up $0.11 during mid-day trading on Monday, reaching $3.40. The company had a trading volume of 25,494 shares, compared to its average volume of 59,922. The stock has a market cap of $87.35 million, a PE ratio of 85.00 and a beta of 1.27. The company has a 50-day moving average price of $3.52 and a two-hundred day moving average price of $3.98. Eton Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $5.81.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, May 9th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). Eton Pharmaceuticals had a return on equity of 5.65% and a net margin of 2.66%. The company had revenue of $7.97 million during the quarter, compared to analyst estimates of $8.30 million. During the same quarter in the previous year, the firm earned ($0.10) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC grew its holdings in shares of Eton Pharmaceuticals by 13.7% during the first quarter. Acadian Asset Management LLC now owns 156,386 shares of the company’s stock valued at $585,000 after buying an additional 18,898 shares in the last quarter. Westside Investment Management Inc. grew its holdings in shares of Eton Pharmaceuticals by 1.9% during the first quarter. Westside Investment Management Inc. now owns 573,960 shares of the company’s stock valued at $2,152,000 after buying an additional 10,850 shares in the last quarter. Opaleye Management Inc. grew its holdings in shares of Eton Pharmaceuticals by 4.1% during the fourth quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock valued at $11,081,000 after buying an additional 99,617 shares in the last quarter. Victory Capital Management Inc. purchased a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at $123,000. Finally, Acuitas Investments LLC grew its holdings in shares of Eton Pharmaceuticals by 124.7% during the fourth quarter. Acuitas Investments LLC now owns 492,054 shares of the company’s stock valued at $2,155,000 after buying an additional 273,054 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.